Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Eastern Cooperative Oncology Group National Cancer Institute (NCI) |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00074282 |
RATIONALE: Drugs used in chemotherapy, such as pentostatin and cyclophosphamide, work in different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies, such as rituximab and alemtuzumab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Combining chemotherapy with monoclonal antibody therapy may kill more tumor cells.
PURPOSE: This phase II trial is studying how well pentostatin, cyclophosphamide, rituximab, and alemtuzumab work in treating patients with relapsed or refractory B-cell chronic lymphocytic leukemia.
Condition | Intervention | Phase |
---|---|---|
Leukemia |
Biological: alemtuzumab Biological: filgrastim Biological: pegfilgrastim Biological: rituximab Drug: cyclophosphamide Drug: pentostatin |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Open Label |
Official Title: | Phase II Trial of Pentostatin, Cyclophosphamide and Rituximab (PCR) Followed by Campath-1H for Previously Treated Relapsed or Refractory Patients With Chronic Lymphocytic Leukemia |
Estimated Enrollment: | 110 |
Study Start Date: | December 2004 |
Estimated Primary Completion Date: | June 2009 (Final data collection date for primary outcome measure) |
OBJECTIVES:
Primary
Secondary
OUTLINE: This is a multicenter study.
Pentostatin, cyclophosphamide, and rituximab (PCR)* therapy: Patients receive pentostatin IV over 10-30 minutes, cyclophosphamide IV over 30-60 minutes, and rituximab** IV on day 1. Patients also receive filgrastim (G-CSF) or pegfilgrastim subcutaneously (SC) beginning on day 3 and continuing until blood counts recover. Treatment repeats every 28 days for a total of 6 courses in the absence of unacceptable toxicity.
NOTE: *Patients demonstrating progression while receiving PCR must have completed 2 courses of PCR prior to proceeding to alemtuzumab therapy
NOTE: **Patients receive rituximab IV on days 1, 3, and 5 for course 1 only; for courses 2-6, patients receive rituximab on day 1 only
Alemtuzumab therapy: Twelve weeks after completion of PCR therapy, patients receive alemtuzumab SC on days 1, 3, and 5. In the absence of disease progression or unacceptable toxicity, treatment repeats weekly for 4 weeks for patients with complete remission or nodular partial remission (PR) after PCR OR for 18 weeks for patients with PR, stable disease, or progressive disease after PCR.
Patients are followed every 3 months for 2 years and then every 6 months for 3 years.
PROJECTED ACCRUAL: A total of 26-110 patients will be accrued for this study within 1.5 years.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Diagnosis of B-cell chronic lymphocytic leukemia (CLL) meeting the following criteria:
Phenotypically characterized CLL defined by the following:
Requires chemotherapy, as indicated by any of the following:
Disease-related symptoms
Demonstrated progression after at least 1 course of either an alkylating agent-based or purine nucleoside-based (e.g., fludarabine) regimen OR failed to achieve a meaningful response OR relapsed after prior therapy
PATIENT CHARACTERISTICS:
Age
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
Cardiovascular
Other
PRIOR CONCURRENT THERAPY:
Biologic therapy
Chemotherapy
At least 1 year since prior pentostatin, cyclophosphamide, and rituximab (PCR) therapy
Endocrine therapy
Radiotherapy
Surgery
Other
Study Chair: | Sanford J. Kempin, MD | St. Vincent's Comprehensive Cancer Center - Manhattan |
Investigator: | Neil E. Kay, MD | Mayo Clinic |
Responsible Party: | ECOG Group Chair's Office ( Robert L. Comis ) |
Study ID Numbers: | CDR0000343796, ECOG-2903 |
Study First Received: | December 10, 2003 |
Last Updated: | August 21, 2009 |
ClinicalTrials.gov Identifier: | NCT00074282 History of Changes |
Health Authority: | Unspecified |
refractory chronic lymphocytic leukemia B-cell chronic lymphocytic leukemia |
Leukemia, Lymphoid Pentostatin Immunoproliferative Disorders Immunologic Factors Rituximab Cyclophosphamide Immunosuppressive Agents Leukemia Lymphatic Diseases |
Chronic Lymphocytic Leukemia Leukemia, Lymphocytic, Chronic, B-Cell Alemtuzumab Antineoplastic Agents, Alkylating Antirheumatic Agents Leukemia, B-Cell Lymphoproliferative Disorders Leukemia, B-cell, Chronic Alkylating Agents |
Leukemia, Lymphoid Pentostatin Immunologic Factors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Physiological Effects of Drugs Cyclophosphamide Leukemia Leukemia, Lymphocytic, Chronic, B-Cell Alemtuzumab Therapeutic Uses Alkylating Agents Immunoproliferative Disorders |
Neoplasms by Histologic Type Immune System Diseases Rituximab Enzyme Inhibitors Immunosuppressive Agents Pharmacologic Actions Lymphatic Diseases Neoplasms Myeloablative Agonists Antineoplastic Agents, Alkylating Lymphoproliferative Disorders Leukemia, B-Cell Antirheumatic Agents |